RE: RNS progressing on-going discussions with potential partners28 May 2026 14:51
Nuformix (NFX) is shaping up as a serious licensing candidate in idiopathic pulmonary fibrosis (IPF), built around its lead asset NXP002.
This isn’t just another early-stage biotech story. NXP002 is a reformulated version of tranilast, designed for inhalation, meaning it targets the lungs directly rather than going systemic. In a disease like IPF, where tolerability and long-term use are key, that’s a meaningful differentiator versus existing oral treatments.
What makes this particularly interesting is the tranilast backbone itself. Tranilast isn’t an unknown or unproven compound, it was originally developed and commercialised by Kissei Pharmaceutical. That gives it a known safety and pharmacology profile, which significantly reduces one of the biggest risks in drug development compared to brand new molecules.
NXP002 effectively takes that known biology and combines it with:
* A new inhaled delivery route
* Fresh IP protection
* Targeted application in fibrosis
That combination is powerful. It’s not starting from zero, it’s building on an already validated compound and improving how it’s delivered, which is exactly the kind of de-risked innovation pharma looks for when licensing.
The company now has both US FDA Orphan Drug Designation and European orphan status. That brings:
* Market exclusivity (7 years US / 10 years EU post-approval)
* Reduced regulatory costs
* Increased attractiveness to pharma partners focused on rare disease returns
IPF is also a proven deal market. Large pharma is already active here, including Boehringer Ingelheim (Ofev) and Roche (Esbriet), with others like United Therapeutics and AstraZeneca actively expanding in respiratory and rare disease.
That creates a clear and logical partner universe. These companies already have:
* Commercial infrastructure in lung disease
* Ongoing pipeline needs in fibrosis
* Incentive to acquire or license differentiated assets
Nuformix has already indicated it is engaging with multiple potential partners with the goal of out-licensing NXP002. The key point is that this is no longer just theoretical science, it is an asset being positioned for commercialisation.
At ~£4–5m market cap, the valuation disconnect is obvious. IPF deals regularly involve upfront payments and milestone packages that exceed the entire current value of the company.
A typical re-rate path in this type of situation looks like:
* ~0.2p range: ignored microcap
* ~0.5p: recognised IPF licensing story
* ~1p: deal expectation priced in
* 1.5p–3p+: deal announcement territory
The shift from “interesting science” to “partnerable asset” is where these stocks tend to move fastest, and NFX now has the regulatory backing, a de-risked molecule in tranilast, and a clear commercial pathway that puts it firmly in that transition zone.
Sign In
Follow the stocks
